Annovis Bio, Inc. Profile Avatar - Palmy Investing

Annovis Bio, Inc.

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's di…

Biotechnology
US, Berwyn [HQ]
Revenue Breakdowns

Segment Analysis Beta

The financial segments are sourced from the SEC' 10-K statement.

Revenue By Top Segments

Annovis Bio, Inc. can't present it's sankey chart.

Historical Revenue By Segment

Last 3Y, in million USD

Annovis Bio, Inc. can't present revenue by segment

Get PRO Today

With PRO you can bypass the blur for the segment revenues of Annovis Bio, Inc..

If you want to see a demo, head over to the financial segments of AAPL

End of ANVS's Analysis
CIK: 1477845 CUSIP: 03615A108 ISIN: US03615A1088 LEI: - UEI: -
Secondary Listings
ANVS has no secondary listings inside our databases.